Use access key #2 to skip to page content.

Exact Sciences hits a home run

Recs

4

November 16, 2011 – Comments (3) | RELATED TICKERS: EXAS

The company presented more data supporting their non-invasive screening test for early stage and pre-cancerous lesions for colorectal cancer.

Here is today's 8k: http://files.shareholder.com/downloads/EXAS/1512445218x0xS1104659-11-64511/1124140/1104659-11-64511.pdf

I've said it once, I'll say it again, this is a cheap stock ($8s right now) given its potential.  I think it will go over $20 within 2 years and then become a take-out target at a significant premium to the $20 something price.  JMHO.

 

3 Comments – Post Your Own

#1) On November 16, 2011 at 1:24 PM, portefeuille (99.60) wrote:

Lazard Capital Markets Annual Healthcare Conference presentation

Stephens Fall Investment Conference presentation

Report this comment
#2) On November 16, 2011 at 1:32 PM, portefeuille (99.60) wrote:

it will go over $20 within 2 years and then become a take-out target at a significant premium to the $20 something price

Highly unlikely. EXAS is currently one of the larger positions of my "fund" (see here). There are currently 3700 EXAS shares in the fund with break-even of around -8.34 USD.

 

Report this comment
#3) On November 16, 2011 at 1:41 PM, CCharing (91.53) wrote:

Porte, could you elaborate briefly why you think the shares won't reach $20, or why you don't think they will become a takeout target?

Report this comment

Featured Broker Partners


Advertisement